Skip to main content
. Author manuscript; available in PMC: 2023 May 5.
Published in final edited form as: Arthritis Rheumatol. 2022 Mar 1;74(4):553–569. doi: 10.1002/art.42037

Table 1.

Classes of interventions

Nonsteroidal antiinflammatory drugs Any at therapeutic dosing (ibuprofen, naproxen, tolmetin, indomethacin, meloxicam, nabumetone, diclofenac, piroxicam, etodolac, celecoxib)
Conventional synthetic disease-modifying antirheumatic drugs Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, calcineurin inhibitors (cyclosporin A, tacrolimus)
Biologic disease-modifying antirheumatic drugs Tumor necrosis factor inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol); other biologic response modifiers (abatacept, tocilizumab, anakinra, canakinumab)
Glucocorticoids Oral (any); intravenous (any); intraarticular (triamcinolone acetonide, triamcinolone hexacetonide)